论文部分内容阅读
目的了解低分子肝素治疗肺心病失代偿期的临床疗效。方法将81例肺心病失代偿期患者随机分成研究组40例和对照组41例,对照组给予吸氧、抗感染、强心、利尿等治疗,研究组在对照组基础上给予低分子肝素,对临床资料及治疗结果进行回顾分析。结果研究组总有效率85.7%,对照组总有效率58.5%,两组疗效比较差异有统计学意义(P<0.05)。结论低分子肝素具有抗凝、抗感染、降低血液黏稠度作用,用于治疗肺心病失代偿期临床疗效肯定。
Objective To understand the clinical effect of low molecular weight heparin in the treatment of decompensated pulmonary heart disease. Methods Eighty-one patients with decompensated pulmonary heart disease were randomly divided into study group (40 cases) and control group (41 cases). The control group was given oxygen inhalation, anti-infective, cardiotonic and diuretic treatment. The study group was given low molecular weight heparin , The clinical data and treatment results were analyzed retrospectively. Results The total effective rate was 85.7% in the study group and 58.5% in the control group, with significant difference between the two groups (P <0.05). Conclusion Low molecular weight heparin anticoagulant, anti-infection, reduce blood viscosity, for the treatment of pulmonary heart disease in decompensated clinical efficacy certainly.